|
US7361336B1
(en)
*
|
1997-09-18 |
2008-04-22 |
Ivan Bergstein |
Methods of cancer therapy targeted against a cancer stem line
|
|
EP1411118B1
(en)
*
|
2001-06-22 |
2008-09-03 |
Chugai Seiyaku Kabushiki Kaisha |
Cell proliferation inhibitors containing anti-glypican-3 antibody
|
|
WO2004022597A1
(ja)
*
|
2002-09-04 |
2004-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
|
|
BRPI0311233B8
(pt)
*
|
2002-05-23 |
2021-07-27 |
Sunnybrook And Womens College Health Sciences Centre |
métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra
|
|
EP1671645A4
(en)
*
|
2003-09-04 |
2007-07-25 |
Chugai Pharmaceutical Co Ltd |
REMEDIES AND MEDIUM FOR DETECTING GALLENGIFT CANCER
|
|
CA2544692C
(en)
*
|
2004-07-09 |
2014-04-01 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-glypican 3 antibody
|
|
KR101300546B1
(ko)
|
2004-08-24 |
2013-09-02 |
추가이 세이야쿠 가부시키가이샤 |
항 글리피칸 3 항체를 이용한 어쥬번트 요법
|
|
AU2005297772B2
(en)
|
2004-10-26 |
2011-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-glypican 3 antibody having modified sugar chain
|
|
CN101198698B
(zh)
|
2005-03-31 |
2014-03-19 |
中外制药株式会社 |
通过调节多肽缔合制备多肽的方法
|
|
EP1901573A1
(en)
|
2005-08-03 |
2008-03-19 |
Matsushita Electric Industrial Co., Ltd. |
Base station apparatus, communication terminal apparatus, and multicarrier communication method
|
|
US20070087005A1
(en)
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
|
US7723043B2
(en)
*
|
2006-01-04 |
2010-05-25 |
Picobella, Lp |
Methods for screening for prostate cancer
|
|
CN104761637B
(zh)
|
2006-03-31 |
2021-10-15 |
中外制药株式会社 |
调控抗体血液动力学的方法
|
|
EP2009101B1
(en)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
DK2178921T3
(en)
*
|
2007-07-17 |
2016-04-04 |
Squibb & Sons Llc |
Monoclonal antibodies to glypican 3
|
|
EP3415529B1
(en)
|
2007-09-26 |
2020-11-04 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
|
CN101874042B9
(zh)
|
2007-09-26 |
2019-01-01 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
|
EP2196541B1
(en)
|
2007-09-28 |
2012-11-07 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-glypican-3 antibody having improved kinetics in plasma
|
|
BRPI0821110B8
(pt)
*
|
2007-12-05 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
|
|
CL2009000647A1
(es)
*
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
|
EP2275443B1
(en)
|
2008-04-11 |
2015-12-02 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
TWI682995B
(zh)
|
2009-03-19 |
2020-01-21 |
日商中外製藥股份有限公司 |
抗體恆定區域改變體
|
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
JP5837821B2
(ja)
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
US10435458B2
(en)
|
2010-03-04 |
2019-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variants with reduced Fcgammar binding
|
|
KR101962483B1
(ko)
|
2010-11-17 |
2019-03-29 |
추가이 세이야쿠 가부시키가이샤 |
혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
|
|
TWI638833B
(zh)
|
2010-11-30 |
2018-10-21 |
中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
|
TWI654204B
(zh)
|
2010-11-30 |
2019-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
具有鈣依存性的抗原結合能力之抗體
|
|
US20120190049A1
(en)
*
|
2010-12-10 |
2012-07-26 |
University Of Washington Through Its Center For Commercialization |
Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles
|
|
CA2827923C
(en)
|
2011-02-25 |
2021-11-23 |
Chugai Seiyaku Kabushiki Kaisha |
Fc.gamma.riib-specific fc antibody
|
|
EP2698431B1
(en)
|
2011-03-30 |
2020-09-09 |
Chugai Seiyaku Kabushiki Kaisha |
Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
|
|
WO2013047752A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
抗原の消失を促進する抗原結合分子
|
|
US20150050269A1
(en)
|
2011-09-30 |
2015-02-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
BR112014007484A2
(pt)
|
2011-09-30 |
2017-04-04 |
Chugai Pharmaceutical Co Ltd |
molécula de ligação a antígeno de indução de resposta imune a antígeno alvo
|
|
EP2765192A4
(en)
|
2011-10-05 |
2015-04-15 |
Chugai Pharmaceutical Co Ltd |
ANTIGENBINDING MOLECULE FOR PREPARING A SPACE BETWEEN A PLASMA AND AN ANTIGEN WITH A SACCHARIDE CHAIN RECEPTOR BINDING DOMAIN
|
|
WO2013125667A1
(ja)
|
2012-02-24 |
2013-08-29 |
中外製薬株式会社 |
FcγRIIBを介して抗原の消失を促進する抗原結合分子
|
|
SG10202006507XA
(en)
|
2012-05-30 |
2020-08-28 |
Chugai Pharmaceutical Co Ltd |
Target-tissue-specific antigen-binding molecule
|
|
US9409994B2
(en)
|
2012-06-01 |
2016-08-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High-affinity monoclonal antibodies to glypican-3 and use thereof
|
|
EP4119947A1
(en)
|
2012-12-21 |
2023-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
|
|
TWI693073B
(zh)
|
2012-12-21 |
2020-05-11 |
日商中外製藥股份有限公司 |
對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
|
|
CN105764922B
(zh)
|
2013-09-27 |
2020-07-17 |
中外制药株式会社 |
多肽异源多聚体的制备方法
|
|
AU2014358191B2
(en)
|
2013-12-04 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
|
|
TWI735410B
(zh)
|
2014-05-08 |
2021-08-11 |
日商中外製藥股份有限公司 |
對ｇｐｃ３標的治療劑療法為有效之患者投予的ｇｐｃ３標的治療劑
|
|
US9926377B2
(en)
*
|
2014-05-22 |
2018-03-27 |
Genentech, Inc. |
Anti-GPC3 antibodies and immunoconjugates
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
CN104829704B
(zh)
*
|
2014-12-15 |
2016-08-17 |
河北省科学院生物研究所 |
一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株
|
|
NZ730607A
(en)
|
2014-12-19 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
SG10201710322VA
(en)
|
2014-12-19 |
2018-02-27 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
|
ES2805085T3
(es)
*
|
2015-01-16 |
2021-02-10 |
Glyp Holdings Pty Ltd |
Epítopos de glipicano y usos de éstos
|
|
WO2016125495A1
(en)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
|
TWI873632B
(zh)
|
2015-02-27 |
2025-02-21 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
|
WO2017002934A1
(ja)
|
2015-07-01 |
2017-01-05 |
中外製薬株式会社 |
Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
|
|
US12168061B2
(en)
*
|
2015-08-03 |
2024-12-17 |
Crage Medical Co., Limited |
Antibody against glypican-3 and application thereof
|
|
KR101796688B1
(ko)
|
2015-10-29 |
2017-12-01 |
재단법인 목암생명과학연구소 |
신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
|
|
JP6987068B2
(ja)
*
|
2015-11-09 |
2021-12-22 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia |
癌マーカーおよび治療標的としてのグリピカン２
|
|
WO2017110981A1
(en)
|
2015-12-25 |
2017-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
|
CA3016424A1
(en)
|
2016-03-14 |
2017-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
|
US11767362B1
(en)
*
|
2016-03-15 |
2023-09-26 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
|
|
ES3055961T3
(en)
|
2016-04-28 |
2026-02-17 |
Chugai Pharmaceutical Co Ltd |
Antibody-containing preparation
|
|
BR112019001902A2
(pt)
|
2016-08-05 |
2019-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
composição para profilaxia ou tratamento de doenças relacionadas à il-8
|
|
EP3502250B1
(en)
|
2016-08-22 |
2024-04-24 |
Chugai Seiyaku Kabushiki Kaisha |
Gene-modified rodent expressing human gpc3 polypeptide
|
|
TW202235438A
(zh)
|
2016-11-28 |
2022-09-16 |
日商中外製藥股份有限公司 |
能夠調節配體結合活性的配體結合分子
|
|
EP3603670A4
(en)
|
2017-03-31 |
2021-03-10 |
Public University Corporation Nara Medical University |
MEDICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BLOOD CLOG FACTOR IX ANOMALY WITH A MULTI-SPECIFIC ANTIGIBINDING MOLECULAR FUNCTION OF BLOOD CLOTHING FACTOR VIII
|
|
US11851486B2
(en)
|
2017-05-02 |
2023-12-26 |
National Center Of Neurology And Psychiatry |
Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
|
|
JP7382922B2
(ja)
|
2017-09-20 |
2023-11-17 |
中外製薬株式会社 |
Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン
|
|
TW202600611A
(zh)
|
2017-11-01 |
2026-01-01 |
日商中外製藥股份有限公司 |
生物活性降低之抗體變異體與同功型
|
|
TWI880235B
(zh)
|
2017-11-28 |
2025-04-11 |
日商中外製藥股份有限公司 |
可調整配體結合活性的配體結合分子
|
|
AR114112A1
(es)
|
2018-02-15 |
2020-07-22 |
Seattle Genetics Inc |
Anticuerpos de glipicano 3 y conjugados de los mismos
|
|
JPWO2019230868A1
(ja)
|
2018-05-30 |
2021-06-24 |
中外製薬株式会社 |
単ドメイン抗体含有リガンド結合分子
|
|
TWI809130B
(zh)
|
2018-06-22 |
2023-07-21 |
美商凱特製藥公司 |
嵌合跨膜蛋白及其用途
|
|
MX2021003744A
(es)
|
2018-10-01 |
2021-06-23 |
Adicet Bio Inc |
Composiciones y métodos relacionados con linfocitos t gamma delta modificados y no modificados para el tratamiento de tumores sólidos.
|
|
CA3117212A1
(en)
|
2018-10-23 |
2020-04-30 |
Dragonfly Therapeutics, Inc. |
Heterodimeric fc-fused proteins
|
|
CN113613676A
(zh)
|
2019-03-19 |
2021-11-05 |
中外制药株式会社 |
包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
|
|
JPWO2020246563A1
(enExample)
|
2019-06-05 |
2020-12-10 |
|
|
|
US20220315909A1
(en)
|
2019-06-05 |
2022-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Protease substrate, and polypeptide including protease cleavage sequence
|
|
US12109235B2
(en)
|
2019-06-21 |
2024-10-08 |
Kite Pharma, Inc. |
TGF-beta receptors and methods of use
|
|
EP4138778A1
(en)
|
2020-04-22 |
2023-03-01 |
Dragonfly Therapeutics, Inc. |
Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins
|
|
CN116194124A
(zh)
|
2020-07-31 |
2023-05-30 |
中外制药株式会社 |
包含表达嵌合受体的细胞的药物组合物
|
|
CN117730100A
(zh)
|
2021-06-08 |
2024-03-19 |
凯德药业股份有限公司 |
Gpc3结合分子
|
|
WO2023061505A1
(en)
*
|
2021-10-15 |
2023-04-20 |
Concept To Medicine Biotech Co., Ltd. |
Anti-glypican 3 antibodies
|
|
WO2024255815A1
(zh)
|
2023-06-16 |
2024-12-19 |
信立泰(成都)生物技术有限公司 |
一种抗gpc3抗体或抗原结合片段及其用途
|